Tissue Procurement Core Ready access to both benign and malignant tissue is a valuable resource for cancer investigators. The Tissue Procurement Core is designed to collect and store high quality tissue specimens from a variety of sources and make these available to HCCC investigators based on the science proposed. The Core insures that these activities are performed in compliance with all rules and regulations covering such activity. The Core and its personnel work in cooperation with clinicians from various departments to: 1) Identify and consent patients from whom collection may be appropriate. 2) Work closely with appropriate individuals in the Surgical Pathology Laboratory to insure adequate patient care while maximizing the number of collected specimens 3) Enter information about specimens into a secure data base and store appropriately 4) Implement rigorous quality control procedures 5) Distribute available tissue to investigators for high quality cancer research The HCCC and University of lowa CTSA are collaborating to further strengthen access to biospecimens. The Tissue Procurement Core has implemented CaTISSUE to enhance the informatics infrastructure for Tissue Procurement, and is working to develop an approach to obtaining consent at the time of registration to the medical center, and link tissues with deidentified clinical data, that will further enhance the utility of tissue for HCCC investigators.

Public Health Relevance

The availability of human cancer and normal tissue is vital for basic and translational cancer research. The Tissue Procurement Core provides a centralized, efficient approach to providing this invaluable resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-12S1
Application #
8533966
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-03-31
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$3,000
Indirect Cost
$1,013
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73

Showing the most recent 10 out of 1080 publications